Does Boswellia Reduce Inflammation?
Boswellia, the resin also known as frankincense, has some of the better randomized-trial evidence among herbal anti-inflammatories, concentrated in osteoarthritis. Here is what the studies show, plus dose and safety.
Reviewed by the Sensa Wellness editorial team. Written to reflect current, publicly available inflammation research.
Boswellia serrata has reasonable randomized-trial evidence for reducing joint inflammation and pain, concentrated in osteoarthritis. Double-blind placebo-controlled trials of standardized extracts at about 100 mg per day found significant improvements in pain and physical function over 90 days, with some benefit appearing in as little as 7 days. A systematic review of osteoarthritis supplements rated Boswellia among those with a large effect on short-term pain. Most of the strong evidence is for joint symptoms rather than whole-body CRP.
Boswellia serrata is a tree resin used for centuries in traditional medicine, and it is the source of the aromatic material known as frankincense. Among the many herbal products marketed for inflammation, Boswellia stands out because it actually has decent human trial data, not just cell-culture claims. Its active compounds, the boswellic acids, inhibit an enzyme called 5-lipoxygenase that produces inflammatory molecules called leukotrienes. That specific, well-characterized mechanism is part of why Boswellia has been taken seriously in clinical research on joint disease.
Does Boswellia Reduce Inflammation in Clinical Trials?
Boswellia extracts significantly improved joint pain and function in randomized controlled trials. According to research indexed on PubMed, a 90-day double-blind, placebo-controlled study of standardized Boswellia extracts (100 mg per day) in people with knee osteoarthritis found clinically and statistically significant improvements in pain scores and physical function versus placebo. Notably, one of the extracts produced significant improvement as early as 7 days after starting, and laboratory work in the same study showed the extract inhibited a cartilage-degrading enzyme and an inflammatory adhesion molecule.
Boswellia also holds up in broader evidence syntheses. A large systematic review and meta-analysis of dietary supplements for osteoarthritis, published in a leading sports medicine journal, identified a set of supplements with large and clinically important effects on short-term pain, and Boswellia extract was among the products with meaningful short-term benefit. The honest caveat is that this evidence is concentrated on joint symptoms in osteoarthritis, and there is less direct data showing Boswellia lowers systemic CRP in the general population.
| Outcome | Finding | Evidence strength |
|---|---|---|
| Osteoarthritis pain | Significant reduction vs placebo | Reasonable RCT evidence |
| Physical function | Significant improvement | Reasonable RCT evidence |
| Speed of effect | Benefit as early as 7 days (some extracts) | Trial-level |
| Systemic CRP in general population | Limited direct data | Weak |
How Does Boswellia Work?
Boswellia targets a different inflammatory pathway than most common supplements. Its boswellic acids, especially acetyl-11-keto-beta-boswellic acid (AKBA), inhibit 5-lipoxygenase, the enzyme that converts arachidonic acid into leukotrienes. Leukotrienes are potent inflammatory signals involved in joint inflammation and other processes. By dialing down leukotriene production, Boswellia reduces one specific arm of the inflammatory response. Because standard anti-inflammatory drugs such as NSAIDs mostly target a different enzyme (cyclooxygenase), Boswellia's mechanism is complementary, which is part of the scientific interest in it. Extracts are often standardized to their boswellic acid content, and higher-AKBA formulations have been developed to boost potency.
How Much Boswellia, and Which Extract?
Boswellia doses in trials vary widely depending on the extract and its standardization, from roughly 100 mg per day of a concentrated, high-AKBA extract to 1,000 mg or more per day of less concentrated preparations. The key detail is standardization: a product labeled for its boswellic acid or AKBA content is closer to what has been tested than an unstandardized generic resin. Because formulations differ so much, the dose that worked in one study does not transfer directly to a different product. This is a supplement where reading the label for standardized extract content genuinely matters.
| Measure | Detail |
|---|---|
| Active compounds | Boswellic acids, notably AKBA |
| Main mechanism | 5-lipoxygenase inhibition, lowering leukotrienes |
| Trial dose range | About 100 mg (concentrated) to 1,000 mg+ per day |
| Strongest evidence | Osteoarthritis pain and function |
How Boswellia Compares With Other Joint Options
Boswellia sits within a small group of supplements that have earned genuine, if modest, evidence for osteoarthritis, and understanding that company helps set expectations. The same large systematic review that rated Boswellia favorably for short-term pain also found that widely sold options such as glucosamine and chondroitin were either ineffective or showed only small effects of arguably little clinical importance, while a handful of others, including curcumin and certain collagen preparations, showed larger short-term pain effects. In other words, Boswellia is toward the better-supported end of the joint-supplement spectrum, not the weaker end. Its distinct 5-lipoxygenase mechanism also makes it a plausible complement to other approaches that work on different pathways, which is part of why it appears in combination products.
The honest caveat that runs through this entire category is that the quality of osteoarthritis supplement evidence is often rated low, effects are generally short-term, and long-term benefits are not established. Boswellia is a reasonable option to discuss with a clinician for joint comfort, but it is not a disease-modifying treatment, and it will not rebuild cartilage. It is best framed as symptom support with a decent short-term track record. For a compound with overlapping evidence and a similar profile, see curcumin and inflammation.
Boswellia and Whole-Body Inflammation
A fair question is whether Boswellia does anything for systemic inflammation, the kind captured by a CRP reading, as opposed to localized joint symptoms. The honest answer is that the evidence there is thin. Its trials were designed to measure joint pain and function, and while its mechanism of dialing down leukotriene production is genuinely anti-inflammatory at the tissue level, there is little robust human data showing it lowers circulating CRP in the general population. This is an important distinction for anyone hoping a joint supplement will also improve their whole-body inflammatory profile. Boswellia may ease a sore knee without changing the systemic inflammation that CRP tracks, just as a whole-body anti-inflammatory lifestyle may lower CRP without specifically targeting one joint. The two goals overlap but are not identical, and Boswellia's evidence lives clearly on the joint side.
Is Boswellia Safe?
Boswellia is generally well tolerated in the trials, and the studies above reported safety parameters largely unchanged versus placebo. The most common side effects are mild digestive complaints such as nausea, acid reflux, or diarrhea. Long-term safety data are more limited than for well-established nutrients, and Boswellia can interact with medications processed by the liver and potentially with anti-inflammatory or immune-modulating drugs. Pregnant and breastfeeding people should avoid it because of insufficient safety data. As always, this is general wellness information and not medical advice, so talk to your doctor before taking Boswellia, especially if you take prescription medication or have a chronic condition.
One further practical caution applies specifically to the supplement market around Boswellia. Because the effective products in trials were standardized extracts with defined boswellic acid or AKBA content, the wide range of generic frankincense and boswellia products sold with vague or absent standardization is a real problem for reproducing the evidence. Two bottles both labeled boswellia can differ enormously in their content of the active compounds, which means a disappointing result may reflect a weak product rather than a weak ingredient. If you try Boswellia, treating the label's standardization details as central rather than optional is the single most useful thing you can do to give it a fair test.
The Honest Verdict on Boswellia
Boswellia earns a "reasonable evidence, mostly for joints" rating. Among herbal anti-inflammatories, it is one of the better-supported options, with genuine randomized-trial data showing reduced pain and improved function in osteoarthritis, sometimes quite quickly. Its distinct 5-lipoxygenase mechanism makes it scientifically interesting and complementary to other approaches. The main limitation is scope: most of the strong evidence is about joint symptoms, not broad reductions in systemic inflammation markers like CRP, so it is best thought of as a targeted joint-support option rather than a general anti-inflammatory. If you try it, choose a standardized extract and pair it with the lifestyle foundations that have broader evidence.
Tracking Inflammation While Using Boswellia
If you are using Boswellia for joint comfort but also want to understand your overall inflammatory status, measuring CRP gives you the whole-body picture that a symptom score cannot. CRP responds to lifestyle over weeks, so tracking it alongside any supplement helps separate targeted joint effects from systemic ones. Sensa is a general wellness device that lets you measure CRP at home and follow the trend over time. Sensa is not a diagnostic tool and does not replace clinical testing, and it does not measure joint-specific inflammation, but it does show where your baseline inflammation sits. For related options, read curcumin and inflammation and how to lower CRP levels.
Sources
- Comparative efficacy and tolerability of 5-Loxin and Aflapin against osteoarthritis of the knee: a double-blind, randomized, placebo-controlled clinical study (Int J Med Sci, 2010), via PubMed: doi.org/10.7150/ijms.7.366
- Dietary supplements for treating osteoarthritis: a systematic review and meta-analysis (Br J Sports Med, 2018), via PubMed: doi.org/10.1136/bjsports-2016-097333
- NIH National Center for Complementary and Integrative Health, Boswellia: nccih.nih.gov
Want to see where your overall inflammation sits?
Sensa is a general wellness tool that lets you measure your CRP levels at home. No needles, no clinic visit. Track your baseline over time and see how lifestyle changes move your number.
Buy Now